Medical Device Industry Watches Key Deadlines in Federal Tariff Investigation
Medical device manufacturers, suppliers, healthcare providers, and investors are closely monitoring a federal trade investigation that could reshape the economics of medical technology manufacturing and sourcing in the United States.
The scrutiny stems from a Section 232 national security investigation launched by the U.S. Department of Commerce in September 2025 to examine the country's reliance on imported personal protective equipment (PPE), medical consumables, and medical devices. Section 232 of the Trade Expansion Act of 1962 authorizes the federal government to investigate whether imports of specific products threaten national security and, if so, recommend actions ranging from tariffs and quotas to other trade restrictions.
The investigation is part of a broader trend in Washington toward evaluating critical supply chains through a national security lens. Policymakers from both parties have increasingly expressed concern about U.S. dependence on overseas manufacturing for strategically important industries, including semiconductors, pharmaceuticals, biotechnology, and medical technology. The COVID-19 pandemic further heightened concerns about supply chain resilience after shortages of PPE, ventilators, diagnostic supplies, and other healthcare products exposed vulnerabilities in global manufacturing networks.
Notably, the investigation covers a remarkably broad range of products. According to the Department of Commerce, the review includes everything from surgical masks, gloves, syringes, and IV supplies to pacemakers, heart valves, insulin pumps, diagnostic systems, blood glucose monitors, and advanced imaging equipment.
Although the investigation itself was announced in September 2025, the most consequential phase of the process is approaching. As the statutory review period of 270 days draws to a close, industry stakeholders are increasingly focused on what recommendations may ultimately be delivered to the President and whether they could result in tariffs, quotas, exemptions, or other trade measures. Because the administration has used Section 232 investigations as the basis for tariff actions in several other industries, medical device manufacturers are treating the summer of 2026 as a potentially important inflection point for future sourcing, manufacturing, and investment decisions.
For medical device companies, the stakes are considerable. Supporters of trade action argue that tariffs could encourage additional domestic manufacturing, reduce dependence on foreign suppliers, and strengthen the resilience of healthcare supply chains. Some policymakers also view tariffs as a tool to counter foreign subsidies and other trade practices that may disadvantage U.S. manufacturers.
At the same time, industry organizations have urged policymakers to recognize the unique characteristics of the medical technology sector. In a statement responding to the investigation, AdvaMed President and CEO Scott Whitaker described medtech as a "uniquely American manufacturing success story," noting that approximately 70 percent of the medical technologies used in the United States are manufactured domestically and that medtech manufacturing employment has grown significantly faster than overall manufacturing employment in recent years.
In subsequent comments submitted to the Commerce Department on behalf of more than 600 member companies, AdvaMed argued that the United States remains the world's leading exporter of medical technology and urged policymakers to pursue strategies that strengthen domestic manufacturing while preserving access to trusted international supply chains and export markets. The association recommended policies such as reciprocal tariff-free trade arrangements with key allies, efforts to address unfair foreign market access barriers, and domestic policies that enhance U.S. competitiveness.
AdvaMed has also cautioned that broad tariffs could have unintended consequences. Medical devices are often manufactured through highly integrated global supply chains, with components, materials, and subassemblies sourced from multiple countries before final assembly. Industry representatives have warned that higher tariff costs could reduce investment, increase healthcare costs, and ultimately affect patient access to critical technologies without necessarily producing the desired increase in domestic manufacturing capacity.
The potential impact extends beyond large multinational manufacturers. Startups, contract manufacturers, suppliers, and healthcare providers could also face higher costs if tariffs are applied to imported components or finished products. For Michigan's growing medical technology ecosystem, the investigation could influence manufacturing strategies, supplier relationships, capital investment decisions, and long-term supply chain planning.
Although the outcome remains uncertain, the investigation underscores a broader shift in federal policy. Trade, industrial competitiveness, healthcare preparedness, and national security are becoming increasingly interconnected. Whether the final result is new tariffs, targeted exemptions, incentives for domestic manufacturing, or a combination of approaches, the decisions made in the coming months could have lasting implications for the medical device industry.
MichBio will continue monitoring developments and assessing potential impacts on Michigan's medical device and life sciences ecosystem. Companies with concerns or perspectives on the investigation and its potential consequences are encouraged to share their views with MichBio as policymakers weigh the future of U.S. medical technology supply chains.
